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Abstract 
Several myeloid precursors of antibacterial peptides have recently been shown to share homologous pre- and pro-regions. Taking advantage of 
this homology, a novel cDNA was cloned from pig bone marrow RNA. This encodes a 166-residue polypeptide with highly conserved pre- (29 
residues) and pro- (101 residues) sequences, followed by a unique, 36-residue C-terminal sequence. Structure analyses of this C-terminal region have 
identified a highly cationic sequence predicted to adopt an amphipathic a-helical conformation. A peptide corresponding to this sequence was 
chemically synthesized and shown to arrest the growth of both Gram-positive and Gram-negative bacteria. At least for Escherichia coli, the activity 
of this peptide appears to be mediated by its ability to permeabilize the bacterial membranes. 
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1. Introduction 
cDNA sequencing of a variety of precursors of anti- 
bacterial peptides synthesized in bovine, porcine and 
rabbit myeloid cells, has predicted the existence of a 
family of precursors with highly homologous signal se- 
quences and pro-regions [l-7]. In all these pre-proforms 
the C-terminal regions, which vary from 12 to 46 residues 
in length, are heterologous and correspond to known 
antibacterial/LPS binding peptides. The conserved pro- 
region also displays a striking level of homology (70- 
95%) with the cathepsin L inhibitor cathelin, isolated 
from pig leukocytes [8,9]. Studies carried out with pro- 
Bac5, one of the earlier proforms of this kind to be 
identified and purified [lo], indicate that the antibacterial 
activity is expressed only after proteolytic release of the 
C-terminal region [11,12]. 
By using oligonucleotide primers derived from the 
conserved N-terminal pro-region, we have amplified sev- 
eral cDNAs from pig myeloid mRNAs, which encode 
polypeptides containing a cathelin-like domain. This do- 
main precedes sequences corresponding to previously 
isolated antibacterial peptides in some cases [13,14], 
while in others it is followed by previously unknown 
sequences with structural characteristics consistent with 
antibacterial activity. 
*Corresponding author.Fax: (39) (40) 398 985. 
In this paper we report the cloning of a cDNA encod- 
ing a precursor with a pro-region that is 90% homolo- 
gous to cathelin, and which contains a novel, highly 
cationic, 36 residue C-terminal region. The latter se- 
quence was termed PMAP-36 from ‘pig myeloid anti- 
bacterial peptide’. We synthesized a peptide correspond- 
ing to a stretch of 20 residues within PMAP-36 which 
was predicted to have a strong tendency to form an 
amphipathic a-helix, and which contained most of its 
cationic residues. Synthetic PMAP-36(1-20) was found 
to have a potent antibacterial activity against both 
Gram-negative and Gram-positive bacteria, and to per- 
meabilize the inner membrane of E. coli. 
2. Materials and methods 
2.1. cDNA cloning, sequencing and Northern analysis 
Total RNA was extracted from pig bone marrow cells with guanidin- 
ium thiocyanate [15]. The experimental conditions to obtain the 3’ and 
5’ ends of PMAP-36 cDNA were as described in [5]. To obtain the 3’ 
end, the antisense primer adaptor 5’-TCGGATCCCTCGAGAA- 
GC(Tl8)-3’ was used for reverse transcription. The sense oligonucleo- 
tide 5’-CGCGAATTCTGTGAGCTTCAGGGTG-3’, common to pre- 
viously described precursors [l-5], and the antisense primer adaptor 
5’-CGAGCTCGGATCCCTCGAGAAGCIT-3’ were used for PCR 
amplification. To obtain the 5’ end of PMAP-36 cDNA, the antisense 
oligonucleotide primer 5’-CACACCATTTACCCACAACCCA-3’, de- 
rived from the unique PMAP-36 cDNA sequence, was used for reverse 
transcription. The unique antisense oligonucleotide primer 5’-CCAG- 
AATTCTTCAAAACCTTCCCGATCTTC-3’ and the sense oligonu- 
cleotide primer 5’-CAAGAATTCTCACCTGGGCACCATG-3’, de- 
rived from a 5’-conserved sequence of homologous precursors, includ- 
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ing a short 5’untranslated region [4], were used for PCR amplification. 
Amplified cDNAs were cloned in Bluescript SK’ vector (Stratagene, 
San Diego. CA) and sequenced on both strands as reported [3]. 
Northern analysis was performed under experimental conditions pre- 
viously described [5]. The 3’-end amplified PMAP-36 cDNA (nt 224 
586). 32P-labelled using standard protocols, was used to hybridize 
Northern blots of pig bone marrow total RNA. 
2.2. Sequence analysis 
cDNA sequence analysis was performed as described [3]. Homology 
searches were carried out on the Swiss-Prot database using the Seq. 
FastDB and Genalign programs in the Intelligenetics uite v. 5.4. Pre- 
diction of the secondary structure of the peptide was obtained using the 
PhD programme provided by the EMBL [16] and compared to that 
obtained with the algorithms of Chou and Fasman [17] and of Garmer 
et al. [18], as present in programs from the GCG and Intelligenetics 
suites. 
2.3. Peptide synthesis and analytical assays 
A Milligen 9050 synthesizer, loaded with Fmoc-Val substituted PEG- 
PS resin (0.1 mmol) (Milligen, Bedford, MA), was used for solid-phase 
synthesis. The Fmoc-protected amino acid (Milhgen or Novabiochem, 
Laufelfingen, Switzerland), N-hydroxybenzotriazole (Aldrich-Chemie, 
Steinhelm, Germany), and 2-(lH-benzotriazole-I-yl)-1,1,3.3-tetrameth- 
yluronium tetrafluoro-borate (Novabiochem) were added in a fivefold 
molar excess for each coupling step, except for residues 2,5,9,13 where 
a sixfold excess was used. Side-chain protection was as follows: trityl 
(Gln), t-butyl (Glu. Asp, Thr), t-butyloxycarbonyl (Lys, Trp) and 
2,2,5,7,8-pentamethylchroman-6-sulphonyl (Arg). Cleavage from the 
resin and deprotection was carried out using a mixture of 95% TFA and 
2.5% each of phenol and water. The peptide was repeatedly extracted 
with ether, and purified by RP-HPLC on a Cl8 column (Delta-Pak, 
Waters, Bedford, MA), using a O-60% acetomtrile gradient in 0.05% 
TFA. 
Peptide concentration was determined by absorbance at 214 nm as 
described by Buck et al. [19]. Amino acid analysis was performed using 
the Pica-Tag system (Waters) [20], and the molecular mass determined 
on an API III ion spray mass spectrometer (PE SCIEX, Toronto, 
Canada). Circular dichroism was carried out on a Jasco J-600 spectro- 
polarimeter, with a cell path length of 2 mm, using 0.1 mg/ml of peptide 
in 5 mM sodium phosphate buffer, pH 7.0, containing 045% (v/v) 
trifluoroethanol. The a-helical content was evaluated by the CONTIN 
program [21] and according to Wu et al. [22], using mean molar residue 
ellipticities of -2000 and -32000 deg. cm’. dmol-’ at 222 nm for 0% and 
100% helix content, respectively. 
2.4 Antibacterial and membrane permeabilization activitres 
The minimal inhibitory concentration (MIC) of the purified peptide 
was determined as described previously [lo] against the following 
strains of bacteria: Escherichla coli ML35 and ATCC 25922. Salmonella 
typhimurium ATCC 14028, Pseudomonas aeruginosa ATCC 27853, Ba- 
cillus megaterrum (local isolate), and Staphylococcus aureus ATCC 
25923 strains. 
Permeabihzation of the inner membrane of the lactose permease 
deficient, p-galactosidase constitutive E. coli ML-35 strain was evalu- 
ated by following the unmasking of /3-galactosidase, asreported [23]. 
Hemolytic activity was determined by using human erythrocytes pre- 
pared from fresh, anticoagulated blood, as described previously [24]. 
Zero and 100% hemolysis were determined in the absence of additives 
and the presence of 0.2% Triton X-100, respectively. Melittin (Sigma 
Chemical Co., St. Louis, MO) was used as a positive control. 
3. Results and discussion 
PCR amplification of the 5’ and 3’ ends of pig bone 
marrow cDNA was performed using sense oligonucleo- 
tide primers corresponding respectively to nt -13 to +2 
and 224 to 240 in Fig. 1. These derive from a 5’ mRNA 
sequence which is common to previously described an- 
timicrobial peptide precursors [l-5]. Several cDNAs 
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-13 TCACCTGGGCACC 
1 ATGGAGACCCAGAGGGCCAGCCTGTGCCTGGGGCGCTGGTCACTG 
ME T Q R A S LCLGRWSL 15 
46 TGGCTTCTGCTGCTGGGACTCGTGGTGCCCTCGGCCAGCGCCCAG 
WLLLLGLVVPSASAQ 30 
* 
91 GCCCTCAGCTACAGGGAGGCCGTGCTTCGTGCTGTGGATCGCCTC 
ALSYREAVLRAVDRL 45 
136 AACGAGCAGTCCTCGGAAGCTAATCTCTACCGCCTCCTGGAGCTG 
NEQSSEANLYRLLEL 60 
181 GACCAGCCGCCCAAGGCCGACGAGGACCCGGGCACCCCGAAACCT 
DQPPKADEDPGT PKP 75 
226 GTGAGCTTCACGGTGAAGGAGACTGTGTGTCCCAGGCCTACCTGG 
v S FTVKETVCPRPTW 90 
271 CGGCCCCCGGAGCTGTGTGACTTCAAGGAGAACGGGCGGGTGAAG 
RPPELCDF K E N G R v K 105 
316 CAGTGTGTGGGGACAGTCACCTTGAACCCATCCAATGACCCACTG 
QC V G T V T L N P S N D P L120 
361 GACATCAACTGTGATGAGATCCAGAGTGTTGGACGATTTAGACGG 
D I NC D E IQ S VCRFRR135 
I____-_(____--,_____,_____(--____--_-____-___-_, 
406 TTGCGTAAGAAGACCCGAAAACGTTTGAAGAAGATCGGGAAGGTT 
I R K K T R K R L K K I C K V 150 
,____-______-________~__________--______----- 
451 TTGAAGTGGATTCCTCCCATTGTCGGCTCAATACCCTTGGGTTGT 
6 K W I P P I V C S I P I, C C 165 
---------__,__--(-__,__---p-____-_----__~_----- 
496 GGGTAAATGGTGTGACCATGGAAGAACCCTAAATATGCCTGCTCT 
c * 166 
--I 
541 GGTGCACAATATGAGTCTGAGUTTCTATGAAAGCTTCTT 
586 C(A), 
Fig. 1. Nucleotide and deduced amino acid sequence of pre-proPMAP- 
36. Nucleotides are numbered on the left and amino acids on the right. 
The end of the putative signal sequence, the stop codon, and the polyad- 
enylation signal are indicated by an arrow, asterisk, and double under- 
line, respectively. The C-terminal region following the cathelin domain 
is shown in bold and segments predicted to have a-helical (a), B-sheet 
@) and loop (I) conformations are indicated. 
with homologous 5’ regions were amplified. Three of 
these were found to encode the precursors of the anti- 
bacterial peptides PR-39 [4], protegrin PG-2 [5] and 
PMAP-23 (Zanetti, M. et al., unpublished), respectively. 
A fourth cDNA sequence showed an open reading frame 
of 166 codons, which corresponded to a transcript of 
about 0.8 kb, as detected by probing a Northern blot of 
pig bone marrow RNA with the 3’ end amplification 
product (not shown). The nucleotide and deduced amino 
acid sequence of this cDNA. obtained from two overlap- 
ping clones extending from nt -13 to +457 and from nt 
+224 to the polyadenylated tail, is shown in Fig. 1. The 
predicted polypeptide has a mass of 18648 Da and a 
calculated p1 of 10.13. The N-terminal region of this 
polypeptide (residues 1 to 130) is 90-94% homologous 
to corresponding regions of previously described precur- 
sors of pig antibacterial peptides (Fig. 2) and includes 
a 29-residue signal peptide and a 101 residue pro-se- 
quence which is about 88% homologous to pig cathelin 
(Fig. 2). The conserved region is followed by a unique, 
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PMAP-36 METQRASLCLGRWSLWLLLLGLWPSASAQALSYREAVLRAVDRLNEQSSEANLYRLLELDQPPKRDEDPGTPKPVSFTVKETVC 
PMAP-23 METQRASLCLGRWSLWLLLLGLWPSASAQALSYREAVLRAVDRLNEQSSEANLYRLLELDQPPKADEDPGTPKPVSFTVKETVC 
PG-2 METQRASLCLGRWSLWLLL~WPSASAQALSYREAVLRAVDRLNEQSSEANLYRLLELDQPPKADEDPGTPKPVSFTVKETVC 
PR-39 
CATHELIN 
REAVLRAVDRLNEQSSEANLYRLLELDQPPKADEDPGTPKPVSFTVKETVCP 
REAVLRAVDRLNEQSSEANLYRLLELDQPPKADEDPGTPKPVSFTVKETVC 
PMAP-36 
PMAP-23 
PG-2 
PR-39 
CATHELIN 
rfrrlrkktrkrlkkigkvlkwippivgsiplgcg 
iidllwrvrrpqkpkfvtvwvr 
ggrlcycrrrfcicvg 
rrprppylprp+pppffpprlppr~ppgfpprfpprfpp~fpgk~ 
Fig. 2. Alignment of the precursor of PMAP-36 with other pig myeloid precursors and cathelin. The sequence is deduced from cDNA [4,5], except 
for cathelin, where it was determined by Edman degradation [9]. Residues homologous to those m PMAP-36 are boxed. 
36-residue C-terminal sequence encompassing residues 
13 1 to 166. This sequence is highly cationic, due to the 
presence of seven lysines and six arginines among the 
first 23 residues (Fig. 1). A valyl-residue is present at 
position 130, which is highly conserved in this precursor 
family [ 1,3-51, and is likely to be the proteolytic cleavage 
site responsible for release of antibacterial peptides from 
their precursors [ 1,3-5,121. 
A structure prediction analysis was carried out on 
proPMAP- using three different algorithms (see sec- 
tion 2). The sequence between residues 132-154 obtained 
a high score for a-helix formation in all three methods. 
This region is comprised within the C-terminal PMAP- 
36 peptide and includes a segment which is by far the 
most cationic of the whole polypeptide. A helical wheel 
projection of the sequence between residues 131-150 
(Fig. 3) shows the amphipathic nature of the predicted 
a-helix, a feature common to several antibacterial pep- 
tides [25,26]. This figure shows a dominant hydrophilic 
domain that subtends an angle of 260” on the projection, 
and a 100” hydrophobic domain. The only residues that 
do not fit this pattern, apart from Gly-1 and Val-20, 
which begin and end the amphipathic helix, are Gly-18 
in the hydrophilic sector and Thr-10 in the apolar sector. 
Given the hydropathic characteristics of this two amino 
acids, they are unlikely to greatly affect the amphiphilic- 
ity of the helix. 
Table 1 
Antibacterial activity of PMAP-36 
- 
Organism and strain MIC (uM) 
Ewherichia coli ML 35 
Escherichia coli ATCC 25922 
Salmonella typhimurium ATCC 14028 
P.reudomonas aeruginosa ATCC 25873 
Bacillus megaterium (local isolate) 
Staphylococcus aureus ATCC 25923 
12 
12 
48 
3 
3 
6 
MIC was defined as the lowest concentration of peptide preventing 
visible bacterial growth after 18 h incubation with PMAP-36 at 37°C. 
as described previously [lo]. Results, determined with approximately 
1.5 x lo5 colony forming units/ml, are the mean of at least five inde- 
pendent determinations with a divergence of not more than one MIC 
value with respect o those here reported. 
This sequence between residues 13 l-l 50 shows a mod- 
erate homology (35%) to a corresponding region of rab- 
bit leukocyte CAP18 [6], a LPS binding polypeptide with 
a cathelin-like domain. The equivalent peptide from 
CAP18 has been synthesized and shown to assume an 
amphipathic a-helical conformation and to exert a very 
potent antibacterial activity (Tossi A. et al., unpub- 
lished). 
The structure prediction studies suggested thus that a 
peptide corresponding to residues 131-l 50 in Fig. 1 
might possess antibacterial activity. This peptide, termed 
PMAP-36( l-20) was chemically synthesized and puri- 
fied by HPLC with a reverse phase column. Mass spec- 
trometry (measured mass of 2524.6 vs. the calculated 
mass of 2525.2 Da), amino acid analysis and analytical 
RP-HPLC (not shown) confirmed the identity and ho- 
mogeneity of the purified peptide. 
To test the predicted structure, circular dichroism 
spectra of PMAP-36(1-20) were recorded in aqueous 
environment and in the presence of trifluoroethanol. The 
spectra of the peptide in aqueous buffer were character- 
istic of an unordered structure, with no helical content 
(Fig. 4). Addition of trifluoroethanol induced a confor- 
mational change in PMAP-36( l-20) which exhibited an 
increasing level of helical folding (Fig. 4 and Fig. 4 inset). 
At 30% and 45% trifluoroethanol, respectively, a-helical 
content of 45% and 75% was estimated using both the 
K 
K G K 
Fig. 3. Helical wheel representation of PMAP-36(1-20). Charged and 
strongly hydrophobic residues are indicated in bold and italics, respec- 
tively. 
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200 Nn 220 240 
Fig. 4. CD spectra of PMAP-36(1-20). Spectra were taken in 5 mM 
phosphate buffer (pH 7) containing no additives (-) and 45% TFE 
f---). The change in mean residue eilipti~ity at 222 nm (@,,) with % TFE 
is shown in the inset. 
CONTIN program [21] and the method of Wu et al. 
PI. 
PMAP-361 l-20) displays in vitro antibacterial activity 
against several Gram-negative and Gram-positive mi- 
croorganisms (Table 1). Maximal activity is exerted 
against f! aeruginosa, B. megaterium and S. aureus 
(MICs of 3-6 FM). What is peculiar is the high activity 
towards R aeruginosa, which is usually more resistant 
than other species to antibacterial peptides [ 10,24,27], 
and the relatively poor activity against S. typhimzurium, 
a species quite susceptible to other antibacterial peptides 
PO]- 
The amphipathic nature of PMAP-36( l-20) suggested 
it might act by permeabilizing the membranes of suscep- 
tible microbes, This was tested by measuring the un- 
masking of the cytosolic enzyme j?-galactosidase in the 
E. coli ML35 strain. The peptide induces permeabiliza- 
tion of the bacterial inner membrane at lo-50 PM, while 
not inducing lysis of human erythrocytes even at a con- 
centration of 100 ,uM. The kinetics of permeabilization 
is slower than for the ProlArg-rich antibacterial peptides 
Bac5 and Bac7 [23] or PMAP-23 (Zanetti, M. et al., 
unpublished), under the same conditions. The rate of 
reaction of the enzyme at steady state, relative to soni- 
cated bacteria, is an order of magnitude lower for 
PMAP-36(1-20~ than for Bac5. These observations may 
in part explain the somewhat lower activity of PMAP- 
36( l-20) towards E. coli ML35 (MIC of 12 ,uM) as com- 
pared to BacS, Bac7 or PMAP-23 (MICs of 2 ,uM). 
These results demonstrate that PMAP-36(1-20) is a 
potent, membrane-active antibacterial peptide. This pep- 
tide and the homologous peptide derived from rabbit 
CAP18 (Tossi, A. et al., unpublished) are new examples 
of a-helical antibacterial peptides. This structural motif 
is common in insect 1251 and amphibian [26} antibacterial 
peptides, but to our knowledge was not found in mam- 
malian antibacterial peptides, with the possible exception 
of porcine Pl cecropin [28]. Furthermore, PMAP-36 and 
the C-terminal domain of CAP18 are the only anti- 
bacterial peptides derived from cathelin-containing pre- 
cursors with an amphipathic a-helical motif. 
The identification of cDNAs encoding polypeptides 
with a cathelin-like pro-region is a rapid and powerful 
strategy for obtaining novel antimicrobial agents. This 
is achieved by combining structure prediction analysis of 
the deduced amino acid sequence with the chemical syn- 
thesis of the C-terminal region corresponding to the pu- 
tative antibacterial domain. 
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